Company / Depreciation & Amortization
FATE THERAPEUTICS INC Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$19.0M
FY2025
5-year range
$2.2M / $19.0M
FY2021-FY2025
Trend
+3.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has increased for 9 consecutive years, from $496,000 in FY2016 to $19M in FY2025.
Based on SEC 10-K filings.
$19M in FY2025 with a 5-year CAGR of +73.6%.
Increased from $14M to $19M over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +83.1%
- 5-Year CAGR
- +73.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- FATE THERAPEUTICS INC's depreciation & amortization has grown for 9 consecutive years.
- 5-year CAGR of +73.6%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 3.7% year-over-year.
- Lowest depreciation & amortization in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.0M | +3.7% |
| FY2024 | $18.3M | +32.9% |
| FY2023 | $13.8M | +345.7% |
| FY2022 | $3.1M | +40.8% |
| FY2021 | $2.2M | +82.1% |
| FY2020 | $1.2M | +24.0% |
| FY2019 | $971.0K | +10.2% |
| FY2018 | $881.0K | +28.2% |
| FY2017 | $687.0K | +38.5% |
| FY2016 | $496.0K | -13.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026